Key facts
- This page summarizes Bryan Ball's Form 4 filing for Aadi Bioscience, Inc. (WHWK).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2025, 18:09.
Bryan Ball - 01 Mar 2025 Form 4 Insider Report for Aadi Bioscience, Inc. (WHWK)
- Reporting relationship
- Chief Technical Operations Officer and SVP, Manufacturing Operations
- Issuer ticker
- WHWK
- Reported as of
- 01 Mar 2025
- Net transaction value
- +$234,955
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 18:09:52 UTC
- Prior SEC filing
- 26 Apr 2024
- Next SEC filing
- 03 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Rodin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bryan Ball filed Form 4 for Aadi Bioscience, Inc. (WHWK) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 26 Apr 2024.
- Current net transaction value: +$234,955.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AADI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,000
- Change %
- +5%
- Price
- Shares after
- 105,000
- Date
- 01 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
AADI
transaction
Common Stock
Sale
- Transaction value
- $5,045
- Shares
- -2,147
- Change %
- -2%
- Price
- $2.35
- Shares after
- 102,853
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F2
AADI
transaction
Common Stock
Award
- Transaction value
- $240,000
- Shares
- +100,000
- Change %
- +97%
- Price
- $2.40
- Shares after
- 202,853
- Date
- 04 Mar 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AADI
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock.
Footnote F2
Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest each of the next three Vesting Commencement Date anniversaries thereafter. "Vesting Commencement Date" shall mean March 1, 2024.
SEC remarks
Chief Technical Operations Officer and SVP, Manufacturing Operations